Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

Haematologica, Vol 92, Issue 1, 106-109 doi:10.3324/haematol.10185
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pelizzari, A. M.
Right arrow Articles by Rossi, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pelizzari, A. M.
Right arrow Articles by Rossi, G.

Acute Myeloid Leukemia

Recombinant granulocyte-colony stimulating factor as treatment for poor prognosis oligoblastic acute myeloid leukemia in elderly patients

Anna Maria Pelizzari, Monica Drera, Mariella D’Adda, Marco Ungari, Daniela Marocolo, Fabio Facchetti, Daniela Bellotti, Sergio Barlati, Giuseppe Rossi

From the Divisione Ematologia, Spedali Civili (AMP, MD, MD’A, GR); I Servizio di Anatomia Patologica Spedali Civili, Cattedra di Anatomia Patologica, Università degli Studi di Brescia (MU, DM, FF); Dipartimento di Scienze Biomediche e Biotecnologie, Sezione di Biologia e Genetica, Università degli Studi di Brescia, Brescia, Italy (DB, SB)

Correspondence: Giuseppe Rossi, M.D., Divisione Ematologia, Spedali, Civili P. le Spedali Civili, 1 25123, Brescia, Italy., E-mail: rossi{at}med.unibs.it

Twenty-five elderly patients with oligoblastic acute myeloid leukemia (AML) received subcutaneous granulocyte colony-stimulating factor (filgrastim) in addition to supportive care. Ninety-two percent of the patients had multilineage dysplasia, 17% hypoplasia, and 48% a high-risk karyotype. During filgrastim treatment neutrophil and platelet counts increased significantly (p<0.0001 and (p=0.042), respectively) and 3/13 patients (23%) no longer required transfusions. A complete peripheral hematologic response (CHR) was obtained in eight (32%) and marrow blast cell clearance (<5%) in five patients (20%), lasting 12 and 10 months, respectively. Filgrastim caused osteomyalgia and fever in 20% of cases. The median survival was 8 months overall, and 15 months in patients who achieved a CHR. Filgrastim may be a useful adjunct to supportive care in elderly patients with poor-risk AML.

Key words: acute myeloid leukemia, elderly, G-CSF, therapy.






HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2007 by the Ferrata Storti Foundation.